Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The binding pattern of was
2020-12-14

The binding pattern of 1 was analysed by flexible molecular docking. The LY2090314 inserted into the narrow ATP binding site of CK2 (Fig. 2). As shown the aliphatic chain of 1 was located at the edge of the pocket and established van der Waals interactions with the side chains residues of Ile95, Met
-
The oxidation of the lipid fraction of
2020-12-14

The oxidation of the lipid fraction of meat is an extremely complex process because of the high sensitivity of oxidation products to decomposition, their reactions with other components, the complex effect of catalysts and the presence of antioxidants. These changes are the main cause of limited she
-
Here although tibolone reduced the
2020-12-14

Here, although tibolone reduced the expression of inflammatory genes such as IL6, IL1β, TLR4 and MIR155-3p, in the presence of PA stimulation, it increased the expression of TNF gene. It should be noted that TNF has pleiotropic effects in the CNS, therefore its increased expression does not always i
-
Potential break through technology poised to overcome
2020-12-14

Potential break-through technology poised to overcome these above-mentioned limitations is that of the “substrate mediated enzyme prodrug therapy”, SMEPT (Fig. 1). Learning from the previously established enzyme prodrug therapies (EPT) and specifically the antibody-directed EPT (ADEPT) [12], develop
-
In terms of its protease activity MME has a
2020-12-12

In terms of its protease activity, MME has a broad range of substrates being able to target glucagon, bradykinin, GLP1, and several other umbelliferone synthesis of circulating small molecules [25]. MME has been shown to target free insulin B-chain [32], although whether MME could target and degrade
-
br Results and Discussion br Conclusions Understanding the c
2020-12-12

Results and Discussion Conclusions Understanding the connections between function and fitness is a primary goal of many biological disciplines including systems biology and molecular evolution. While sound approaches have been developed to understand the connections between function and fitnes
-
Current therapeutic interventions are directed both to preve
2020-12-12

Current therapeutic interventions are directed both to prevent (primarily by proper glycemic control) and to treat the advanced stages of diabetic retinopathy, when vision has already been significantly affected. Although these therapies can be very effective in preventing, delaying or reducing visi
-
hcv protease inhibitor Mother rats acutely treated with quin
2020-12-12

Mother rats acutely treated with quinpirole (0.5 and 1.0 mg/kg) decreased the pup exploration time but increased the object exploration, so they showed a significantly lower pup preference ratio. They also showed impaired maternal performance in the home cage, consistent with our previous study (Zha
-
Db model cells showed various aberrant phenotypes that
2020-12-12

Db model cells showed various aberrant phenotypes that seemed to reflect the pathological abnormalities found under diabetic conditions. First, in Db model cells after insulin stimulation, we found the inhibition of the transcriptional repression of the gluconeogenic genes, PCK1 and G6PC, and aberra
-
adrenergic antagonist br Introduction br Sphingolipid metabo
2020-12-12

Introduction Sphingolipid metabolism Sphingolipids, are fundamental constituents of all eukaryotic membranes and their metabolism is carried out by a broad array of anabolic and adrenergic antagonist with ceramide as their hub (for a review, (Hannun and Obeid, 2018)). Ceramide can be formed by
-
Calcium dependence of CaM target
2020-12-12

Calcium dependence of CaM/target interaction was analyzed using a titration matrix in which both Ca2+ and CaM concentrations were changed. This gave us access to different parameters characterizing the interaction and namely to the number of bound Ca2+ required for the interaction to occur. Our app
-
br Cytokines as targets for the development of drugs Since
2020-12-12

Cytokines as targets for the development of drugs Since the first scientific evidence describing the large number of cytokines and their functional roles and involvement in molecular mechanism of various diseases or disorders researchers have targeted cytokines. (Isaacs and Lindenmann, 1957), Des
-
In conclusion we developed a new CysLT and CysLT
2020-12-11

In conclusion, we developed a new CysLT1 and CysLT2 receptors-mediated anaphylaxis guinea pig model that can be useful for screening both CysLT2 receptor and CysLT1/2 receptor antagonists. In addition, we have shown that the dual CysLT1/2 receptor antagonist ONO-6950 can exert protective effect agai
-
During DNA replication p protein
2020-12-11

During DNA replication p21 protein binds PCNA, in its role as processivity factor, to stop replication when there is DNA damage, and apparently p21 also binds PCNA when this is in complex with Cyc/CDKs [11]. In plants, KRPs (functional analogs of p21), inhibit kinase activity in CycD/CDKs complexes
-
br Conclusion br Conflicts of interest br
2020-12-11

Conclusion Conflicts of interest Acknowledgements This study was financially supported by The Science and Engineering Research Board (SERB), Department of Science & Technology (DST), Government of India under the Fast Track Scheme for Young Scientist to Dr. V. Dhananjayan (No: SB/FT/LS-140/
15842 records 721/1057 page Previous Next First page 上5页 721722723724725 下5页 Last page